Gemtuzumab ozogamicin in acute myeloid leukaemia
Authors:
- 1 May 2012
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 9 (6) , 310-311
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyThe Lancet, 2012
- The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized TrialBlood, 2011
- High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraCBlood, 2011
- Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR StudyBlood, 2011
- Cytarabine Dose for Acute Myeloid LeukemiaNew England Journal of Medicine, 2011
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 TrialJournal of Clinical Oncology, 2011
- Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.Blood, 2009
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- High‐dose cytosine arabinoside in the treatment of acute myeloid leukemiaCancer, 2006
- Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.1998